See Bull Run's live pages for Divi's Laboratories and Laurus Labs. For a downstream-pharma contrast, see Bull Run's Dr Reddy's vs Divi's Laboratories comparison.

Q1 FY27 scorecard: similar growth, very different profit density

Both companies are moving toward the same economic prize

The prize is not simply higher pharmaceutical revenue.

It is becoming embedded inside the supply chain of innovator pharmaceutical companies.

A commodity API can face many competitors.

A validated Custom Synthesis or CDMO programme can be much stickier.

The manufacturer may spend years developing the process, optimizing yield, validating the facility and becoming part of the customer's regulatory filing.

Switching suppliers can then become expensive and time-consuming.

Divi's is already heavily exposed to Custom Synthesis

Applied to the ₹3,080 crore quarterly revenue base, the mix implies roughly ₹1,850 crore of Custom Synthesis-related revenue.

That is an approximation based on management's percentage mix—not a separately audited segment figure.

Nevertheless, it demonstrates the scale.

Divi's Custom Synthesis business alone is already substantially larger than Laurus's current CDMO business.

Laurus's CDMO business is smaller but growing much faster

Laurus reported approximately ₹870 crore of Q1 CDMO revenue.

That represented roughly 43% of consolidated revenue.

CDMO revenue increased 67% year on year.

The growth was driven primarily by small-molecule programmes, commercial supplies and late-stage clinical projects.

Laurus Bio also grew, but from a much smaller base.

The 43% figure is strategically important

Laurus's historical earnings depended heavily on affordable medicines, especially antiretroviral APIs and formulations.

Those products created scale but also exposed the company to:

• procurement pricing;
• customer concentration;
• generic competition;
• raw-material cycles;
• lower asset returns during weak utilisation periods.

CDMO changes that mix.

If Laurus succeeds in moving CDMO toward its stated long-term ambition of roughly half of revenue, the company's normalized margins and return profile can become structurally stronger.

Laurus still has a large affordable-medicines engine

Affordable Medicines generated approximately ₹1,156 crore in Q1 FY27 and grew around 10%.

Within that:

• API revenue was approximately ₹654 crore, up around 3%;
• finished-dosage formulation revenue was approximately ₹502 crore, up about 22%.

This business remains important because it provides manufacturing scale and cash generation while the CDMO platform expands.

Divi's generic API business is smaller in mix but still strategically important

Generic products represented around 40% of Divi's Q1 revenue.

The generic API portfolio provides:

• high-volume manufacturing experience;
• customer relationships;
• backward-integration opportunities;
• facility utilisation;
• cash generation outside individual Custom Synthesis campaigns.

Divi's therefore is not a pure-play CDMO.

The margin difference explains why investors pay so much for Divi's quality

Divi's generated approximately ₹1,255 crore of EBITDA from ₹3,080 crore of revenue.

Laurus generated ₹644 crore from ₹2,026 crore.

For every ₹100 of Q1 revenue:

• Divi's retained roughly ₹41 as EBITDA;
• Laurus retained roughly ₹32.

Both are excellent manufacturing margins.

Divi's is simply operating at an unusually high level.

But Divi's 40.8% margin should not be blindly annualised

A manufacturing campaign can shift revenue from one quarter into another.

Generic API pricing can also change.

Currency can affect export realizations.

The better long-term question is whether Divi's can remain a high-30s-margin company as new capacity ramps.

Laurus's 31.8% margin also reflects favourable mix

Laurus's gross margin rose to approximately 62.7%.

EBITDA margin expanded around seven percentage points year on year.

Management attributed the improvement to:

• higher CDMO contribution;
• better manufacturing utilisation;
• operating leverage;
• favourable business mix.

This confirms that Laurus's transition is not simply adding revenue.

It is changing revenue quality.

Laurus generated record quarterly revenue and EBITDA

Q1 FY27 was the strongest quarterly financial result in the company's history.

Revenue increased 29% to ₹2,026 crore.

EBITDA increased around 66% to ₹644 crore.

PAT increased roughly 126% to ₹368 crore.

This is classic operating leverage:

revenue grew 29%, but profit grew more than four times as fast.

Divi's also produced powerful operating leverage

Divi's revenue increased approximately 28%.

EBITDA increased more than 70%.

PAT increased approximately 66%.

The similarity is striking.

Both companies are demonstrating what happens when high-value manufacturing fills existing and newly commissioned assets.

The next phase is about converting capex into utilisation

Indian pharmaceutical outsourcing companies are spending heavily because global customers increasingly want:

• supply-chain diversification;
• China-plus-one manufacturing options;
• complex chemistry expertise;
• regulatory-compliant capacity;
• integrated development and commercial manufacturing;
• peptide and biologic capabilities.

But capex creates value only when customers actually fill the plants.

Laurus raised FY27 capex to approximately ₹2,000 crore

This is a major investment relative to Laurus's current earnings.

Management says the new capacity is not being built merely on speculative demand.

Much of it relates to existing partners, multiple products and near-term customer requirements.

That reduces—but does not eliminate—utilisation risk.

Divi's also has a large commissioning pipeline

Divi's had capital work in progress of approximately ₹2,034 crore around Q1.

The company capitalised roughly ₹451 crore of assets during the quarter.

Three major Custom Synthesis programmes were approaching validation or qualification stages.

That creates a similar future question:

how quickly can newly created assets begin contributing revenue?

Validation is not the same as commercialization

A new CDMO plant can be mechanically complete but economically idle.

Before commercial production, customers may require:

• engineering batches;
• process validation;
• quality testing;
• regulatory filing updates;
• customer audits;
• regulatory approval.

Revenue can therefore lag construction by quarters or even years.

Peptides are a major growth opportunity for both

Demand for peptide drugs is expanding rapidly because of metabolic therapies and other complex medicines.

Peptide manufacturing requires:

• specialised synthesis;
• purification;
• high-quality raw materials;
• scale-up expertise;
• strict impurity control.

This creates high technical barriers.

Divi's is investing in peptide manufacturing at scale

Divi's has been expanding solid-phase and other peptide-synthesis capabilities.

The strategy fits its existing strengths in:

• complex chemistry;
• large-scale manufacturing;
• backward integration;
• high-purity processes.

If peptide programmes reach commercial scale, they can become an important second layer of Custom Synthesis growth.

Laurus is also targeting peptides

Laurus has included peptide-related capabilities within its current expansion programme.

Management expects peptides to become a meaningful future revenue contributor.

This means both companies may eventually compete for similar innovator programmes.

Laurus is making a broader modality bet

Beyond small-molecule CDMO and peptides, Laurus is investing across:

• microbial fermentation;
• precision fermentation;
• biocatalysis;
• gene therapy;
• antibody-drug conjugate capabilities;
• sterile fill-finish;
• viral vectors.

This gives Laurus more optionality—but also creates more technological and capital-allocation complexity.

Laurus Bio remains small today

Laurus Bio generated approximately ₹35 crore of Q1 revenue, up around 21%.

That is only a small percentage of group revenue.

Management expects a longer gestation period before fermentation and biologics meaningfully affect consolidated earnings.

Investors therefore should not value the Bio opportunity as if current revenue is already large.

Its 400-KL-plus fermentation Phase I is approaching operation

Laurus expects the first phase of its new microbial fermentation capacity, slightly above 400 KL, to become operational around the end of calendar 2026.

The capacity is designed to be fungible across multiple programmes.

This is useful because not every molecule in development will succeed.

Fungible infrastructure can be redeployed.

Gene therapy and ADC investments are much longer-dated

Laurus has been clear that several newer modalities may take years to generate meaningful returns.

The company is therefore funding two different horizons simultaneously:

• near-term customer-backed small-molecule and API expansion;
• longer-term bets in biologics, fermentation, ADCs and gene therapy.

This can create substantial future upside if execution is strong.

It can also lower free cash flow during the investment phase.

Divi's strategy is more concentrated

Divi's has historically stayed closer to its core strengths:

• APIs;
• intermediates;
• Custom Synthesis;
• process chemistry;
• large-scale manufacturing;
• select specialised verticals such as peptides and contrast media.

This narrower strategy reduces the number of capital-allocation bets management must get right.

Balance-sheet quality strongly favours Divi's

Divi's standardized debt-to-equity is effectively zero.

Its cash position is substantial.

This lets it fund expansion without relying heavily on financial leverage.

Laurus has a very different balance-sheet structure.

Laurus's expansion is being funded partly through debt

Laurus management reported net debt around ₹2,656 crore after Q1.

Bull Run's standardized debt-to-equity field is approximately 0.45x.

This is not excessive for a profitable manufacturer.

But it means capital allocation matters more.

Every large capacity project needs to earn a return above both the cost of capital and financing costs.

ROCE is surprisingly close

Laurus's current ROCE slightly exceeds Divi's standardized Bull Run figure.

That demonstrates how much its earnings have improved as previously underutilised assets fill.

But the free-cash-flow comparison shows the cost of Laurus's prolonged investment cycle.

Free cash flow is the major quality gap

Divi's has historically converted significant earnings into cash while keeping leverage negligible.

Laurus has been reinvesting aggressively.

That means headline PAT growth does not translate into equivalent free cash flow.

This is not necessarily negative if new investment produces attractive future returns.

But it raises the valuation hurdle.

Valuation is now demanding for both companies

The striking point is that Laurus currently trades at the higher trailing P/E.

This is unusual because Divi's has the higher margin, larger earnings base, stronger balance sheet and longer record of premium manufacturing economics.

The market is therefore pricing substantial future Laurus growth.

Laurus's rerating has been extraordinary

Bull Run's latest one-year return for Laurus is approximately 117%.

Divi's is up around 51%.

Both have rerated strongly.

Laurus has rerated much more.

That means the investment thesis has changed.

Investors are no longer buying an ignored turnaround.

They are buying a high-expectation CDMO growth story.

A high P/E changes what counts as good execution

At 90x-plus trailing earnings, merely growing profit is not enough.

Laurus needs:

• CDMO growth to remain strong;
• new capex to become productive quickly;
• EBITDA margin to remain structurally higher;
• net debt to remain controlled;
• new modalities to eventually create revenue;
• ROCE to remain above the cost of capital.

Any disappointment can compress the multiple.

Divi's valuation hurdle is also extremely high

An 80x-plus P/E assumes years of strong Custom Synthesis growth.

Divi's therefore needs:

• major validation projects to commercialise;
• peptide programmes to scale;
• high margins to remain durable;
• new capex to earn strong returns;
• customer relationships to remain sticky.

Which company has greater Custom Synthesis scale?

Divi's Laboratories.

Its approximate 60% Q1 mix implies Custom Synthesis revenue substantially above Laurus's ₹870 crore CDMO revenue.

The categories are not identical, but the scale difference is meaningful.

Which company is growing CDMO faster?

Laurus Labs currently.

Its Q1 CDMO revenue grew approximately 67%.

The business is approaching half of group revenue and management targets roughly 50% of total revenue from CDMO by FY30.

Which has higher margins?

Divi's Laboratories.

Q1 EBITDA margin was approximately 40.8% versus Laurus at 31.8%.

Which has the stronger balance sheet?

Divi's Laboratories by a wide margin.

It is essentially debt-free, while Laurus is funding a very large expansion programme and carries meaningful net debt.

Which currently has the lower valuation?

Divi's on trailing P/E, surprisingly.

Early-September market data place Divi's around the low-80s P/E and Laurus around the low-90s.

Neither is conventionally cheap.

Which is better: Divi's Laboratories or Laurus Labs?

Divi's Laboratories currently has the stronger proven manufacturing-quality profile. It generates almost twice Laurus's EBITDA, about 2.5 times the PAT, has the higher Q1 margin and operates with essentially no financial leverage.

Laurus Labs currently has the stronger transformation and operating-leverage story. CDMO revenue grew 67%, EBITDA grew 66%, PAT more than doubled, and management is investing aggressively to turn Laurus into a much larger multi-modality CDMO.

The problem for new investors is valuation.

Laurus's transformation is no longer hidden.

The share price has more than doubled over one year and the stock now trades at a higher trailing P/E than Divi's.

At September 2026 valuations, Divi's offers the stronger established quality and balance-sheet profile, while Laurus offers greater proportional growth if customer-backed capex converts successfully. Laurus now requires near-excellent execution to justify its premium valuation; Divi's requires sustained Custom Synthesis growth to defend its own very high multiple.

Frequently asked questions